PharmTech Europe, Weekly Alert
Having trouble viewing this e-mail? CLICK HERE

PharmTech Europe
24 July 2018

PHARMTECH.COM

CURRENT ISSUE

SUBSCRIBE

FORWARD

twitter twitter
advertisement

Top Stories

Novartis Has Production Hiccup for Kymriah CAR-T Therapy

The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
/ read more /


AbbVie Signs Patent License with Mylan for Humira Biosimilar

AbbVie will grant Mylan license to launch a biosimilar to AbbVie's Humira.
/ read more /

Subscribe

Subscribers can enjoy each full issue of Pharm Tech Europe in print, or via Pharm Tech Europe apps.

subscription offers
subscribe
advertisement

Industry News

Drugs Containing Valsartan Recalled

Teva Pharmaceuticals, Major Pharmaceuticals, and Solco Healthcare are voluntarily recalling their products containing valsartan because of the presence of N-nitrosodimethylamine.
/ read more /


Call for Entries: 2018 CPhI Pharma Awards

Annual awards program recognizes innovation in bio/pharmaceutical drug development and manufacturing.
/ read more /


More Industry News
advertisement

Regulatory News

EU and Japan Strengthen Collaboration on GMP Inspection

Both parties have agreed to recognize each other's inspection of manufacturing sites for a broader range of medicines, including sterile products, APIs, biologics, and vaccines.
/ read more /


FDA Sends Warning Letter to California OTC Manufacturer

Inspectors found quality issues at bB BioChem Laboratories Inc, a California-based manufacturer of over-the-counter drug products.
/ read more /


More Regulatory News

Bio/Pharma News

Otsuka to Acquire Visterra for $430 Million

Otsuka Pharmaceutical will acquire Visterra, a clinical-stage biotechnology company focused on developing antibody-based therapies, for approximately $430 million.
/ read more /


Novartis, CELLforCURE Partner to Manufacture CAR-T Therapies

CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.
/ read more /


More Bio/Pharma News

Supplier News

Cambrex to Acquire Halo Pharma for $425 Million

The acquisition will place Cambrex into the finished dosage form CDMO market.
/ read more /


 

Moderna Opens Manufacturing Site for mRNA Therapeutics

Moderna's new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.
/ read more /


More Supplier News

FEATURED TOPICS

PACKAGING

Selecting Primary Packaging for Parenterals

Traditional glass and polymeric materials compete for market share in primary packaging for parenteral drug products.
/ read more /

 

MANUFACTURING

Aseptic Transfer Technology: Weighing Up the Advantages of Varying Approaches for Sterile Drug Manufacturing

The author reviews current approaches to sterile containment and compares several sealed transfer and barrier techniques, including isolators, restricted access barrier systems, and split butterfly valve technology.
/ read more /

EXCIPIENTS

Selecting Excipients for Controlled Release

With the right excipients, formulators can control when, where, and how an API is released.
/ read more /

QUALITY SYSTEMS

Responding to FDA CAPA Requests

Pharmaceutical Technology spoke with Sharon Ayd, executive vice-president of Pre-approval Pharmaceuticals and chief scientific officer at Regulatory Compliance Associates, about developing a corrective action and preventive action (CAPA) plan.
/ read more /


Events

16th International Conference and Exhibition on Pharmaceutical Formulations

Rome, Italy

26–27 July 2018


more events

eBOOKS

Biologics and Sterile Drug Manufacturing 2018

This ebook covers novel technologies for the formulation, manufacture, purification, and delivery of sterile small- and large-molecule drugs, including single-use systems, facilities and equipment, contamination issues, and process analytics.

contribute | CONTACT EDITORS | CONTACT SALES | subscribe | advertise